Heron Therapeutics Inc (NASDAQ:HRTX) – Equities research analysts at Oppenheimer cut their FY2020 EPS estimates for shares of Heron Therapeutics in a report released on Thursday. Oppenheimer analyst D. Archila now forecasts that the biotechnology company will post earnings of $1.32 per share for the year, down from their previous estimate of $1.45. Oppenheimer currently has a “Buy” rating and a $27.00 target price on the stock. Oppenheimer also issued estimates for Heron Therapeutics’ FY2021 earnings at $2.98 EPS.

HRTX has been the subject of a number of other research reports. Mizuho reiterated a “buy” rating and set a $28.00 target price on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Friday, October 20th. Cowen reiterated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research note on Monday, November 6th. BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Wednesday, November 22nd. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $28.73.

Shares of Heron Therapeutics (NASDAQ HRTX) traded up $0.15 during mid-day trading on Friday, hitting $15.55. 1,453,776 shares of the company were exchanged, compared to its average volume of 1,120,000. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $18.40.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HRTX. Legal & General Group Plc boosted its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,098 shares in the last quarter. Quantbot Technologies LP boosted its stake in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares in the last quarter. Trexquant Investment LP acquired a new position in Heron Therapeutics in the third quarter valued at $206,000. Jane Street Group LLC acquired a new position in Heron Therapeutics in the third quarter valued at $223,000. Finally, HighTower Advisors LLC boosted its stake in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/15/oppenheimer-weighs-in-on-heron-therapeutics-incs-fy2020-earnings-hrtx.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.